VelosBio CEO: Series A Success Shows Investors Back His ADC Formula
VelosBio's well-backed Series A funding round showed that investors believe his team has identified the right combination of cancer target, linker and payload for creating a successful novel ADC, the biotech's CEO told Scrip.
You may also be interested in...
Merck continues its cancer deal streak, purchasing a pipeline of antibody-drug conjugates and bispecific antibodies against receptor tyrosine kinase-like orphan receptor 1 (ROR1).
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.